

FORM PTO-1449	O I P E JAN 12 2004 C14 PATENT & TRADEMARK OFFICE	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P0706P2C2D2C1	Serial No. 10/666,689
LIST OF DISCLOSURES REFERENCED BY APPLICANT (Use several sheets if necessary)		Applicant Lee et al.		
		Filing Date 19 Sep 2003	Group 1646	

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date
2	* 1 5,374,506	20.12.94	Murphy, P.			
2	* 2 5,543,503	06.08.96	Chuntharapai et al.			11.06.93

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
2	3 WO 92/04372	19.03.92	PCT				
2	* 4 WO 92/17497	15.10.92	PCT				
2	* 5 WO 92/18641	29.10.92	PCT				
2	* 6 WO 93/06229	01.04.93	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

2	* 7 Antibodies: A Laboratory Manual (Chapter 5), Harlow and Lane, eds., Cold Spring Harbor Laboratory pps. 72-76 (1988)
2	* 8 Beckmann et al., "Molecular characterization of the interleukin-8 receptor" <u>Biochem. & Biophys. Res. Comm.</u> 179(2):784-789 (Sep 16, 1991)
2	* 9 Besemer et al., "Specific Binding, Internalization, and Degradation of Human Neutrophil Activating Factor by Human Neutrophil Activating Factor by Human Polymorphonuclear Leukocytes" <u>Journal of Biological Chemistry</u> 264:17409-17415 (1989)
2	* 10 Bleul et al., "The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes" <u>Proc. Natl. Acad. Sci. USA</u> 94:1925-1930 (March 1997)
2	* 11 Boulay et al., "Synthesis and use of a novel N-formyl peptide derivative to isolate a human N-formyl peptide receptor cDNA" <u>Biochem. Biophys. Res. Comm.</u> 168(3):1103-1109 (1990)
2	* 12 Brennan et al., "Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells" <u>European Journal of Immunology</u> 20:2141-2144 (1990)
2	* 13 Broaddus et al., "Interleukin-8 is a major neutrophil chemotactic factor in pleural liquid of patients with empyema" <u>Amer. Rev. Resp. Disease</u> 146:825-830 (1992)
2	* 14 Chuntharapai et al., "Generation and characterization of monoclonal antibodies (mAbs) to human IL 8 receptor A" <u>J. Immunol.</u> (abstract #708) 150(8(2)):126A (May 1993)
2	* 15 Chuntharapai et al., "Neutralizing monoclonal antibodies to human IL-8 receptor A map to the NH ₂ -terminal region of the receptor" <u>J. Immunol.</u> 152(4):1783-1789 (1994)
2	* 16 Clark-Lewis et al., "Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg" <u>Proc. Natl. Acad. Sci. USA</u> 90(8):3574-3577 (Apr 15, 1993)
2	* 17 Clark-Lewis et al., "Structure-Activity Relationships of Interleukin-8 Determined Using Chemically Synthesized Analogs" <u>Journal of Biological Chemistry</u> 266(34):23128-23134 (1991)
2	* 18 Crockard et al., "Markers of Inflammatory Activation: Upregulation of Complements Receptors CR1 and CR3 on Synovial Fluid Neutrophils from Patients with Inflammatory Joint Disease" <u>Clinical Immunol. & Immunopath.</u> 65(2):135-142 (1992)
2	* 19 D'Andrea et al., "Expression Cloning of the Murine Erythropoietin Receptor" <u>Cell</u> 57:277-285 (1989)
2	* 20 DeForge et al., "Interleukin-1 Receptor Antagonist Protein Inhibits Interleukin-8 Expression in Lipopolysaccharide-stimulated Human Whole Blood" <u>Amer. J. Path.</u> 140(5):1045-1054 (1992)


Examiner	Date Considered
----------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 <i>JAN 12 2004</i>		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P0706P2C2D2C1	Serial No. 10/666,689
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Lee et al.		
		Filing Date 19 Sep 2003	Group 1646	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)				
✓ 21	DeForge et al., "Oxygen Radical Scavengers Selectively Inhibit Interleukin 8 Production in Human Whole Blood" <u>J. Clin. Invest.</u> 90(5):2123-2129 (1992)			
✓ 22	Deleuran et al., "The effect of second-line antirheumatic drugs on interleukin-8 mRNA synthesis and protein secretion in human endothelial cells" <u>Cytokine</u> 4(5):403-409 (1992)			
✓ 23	Dinarello et al., "Anticytokine Strategies in the Treatment of the Systemic Inflammatory Response Syndrome" <u>Journal of the American Medical Assn.</u> 269(14):1829-1835 (1991)			
✓ *24	Dixon et al., "Structural features required for ligand binding to the -adrenergic receptor" <u>EMBO Journal</u> 6(11):3269-3275 (1987)			
✓ *25	Dixon, et al., "Structure-Function Analysis of the Beta-Adrenergic Receptor" <u>Cold Spring Har. Sym. Quant. Biol.</u> 53:487-497 (1988)			
✓ *26	Fedderspiel et al., "Molecular cloning of the cDNA and chromosomal localization of the gene for a putative seven-transmembrane segment (7-TMS) receptor isolated from human spleen" <u>Genomics</u> 16:707-712 (1993)			
✓ *27	Feng, Yu et al., "HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor" <u>Science</u> 272:872-877 (1996)			
✓ *28	Gayle III et al., "Importance of the Amino Terminus of the Interleukin-8 Receptor in Ligand Interactions" <u>Journal of Biological Chemistry</u> 268(10):7283-7289 (1993)			
✓ 29	Gearing et al., "Expression Cloning of a Receptor for Human Granulocyte-macrophage Colony-stimulating Factor" <u>EMBO Journal</u> 8(12):3667-3676 (1989)			
✓ *30	Gerard & Gerard, "The chemotactic receptor for human C5a anaphylatoxin" <u>Nature</u> 349:614-617 (1991)			
✓ *31	Grob et al., "Characterization of a Receptor for Human Monocyte-derived Neutrophil Chemotactic Factor/Interleukin-8" <u>Journal of Biological Chemistry</u> 265(14):8311-8316 (1990)			
✓ 32	Grynkiewicz et al., "A New Generation of Ca ²⁺ Indicators with Greatly Improved Fluorescence Properties" <u>Journal of Biological Chemistry</u> 260(6):3440-3450 (1985)			
✓ *33	Hammond et al., "Generation of neutralizing antibodies to human interleukin-8 (IL8) receptors" <u>J. Cell Biochem. (Suppl. 18B)</u> 318:Abstract #0108 (1994)			
✓ *34	Harada et al. <u>Gene</u> 142:297-300 (1994)			
✓ *35	Hebert et al., "Endothelial and Leukocyte Forms of IL-8: Conversion by Thrombin and Interactions with Neutrophils" <u>J. Immunol.</u> 145(9):3033-3040 (Nov 1, 1990)			
✓ *36	Hebert et al., "Partial functional mapping of the human interleukin-8 type A receptor" <u>Journal of Biological Chemistry</u> 268(25):18549-18553 (1993)			
✓ *37	Hebert et al., "Scanning Mutagenesis of Interleukin-8 Identifies a Cluster of Residues Required for Receptor Binding" <u>Journal of Biological Chemistry</u> 266(28):18989-18994 (1991)			
✓ 38	Hemmi et al., "A novel member of the interferon receptor family complements functionality of the murine interferon γ receptor in human cells" <u>Cell</u> 76:803-810 (1994)			
✓ *39	Herzog et al., "Molecular cloning, characterization, and localization of the human homolog to the reported bovine NPY Y3 receptor: lack of NPY binding and activation" <u>DNA and Cell Biology</u> 12(6):465-471 (1993)			
✓ 40	Hirota et al., "Production of interleukin 8 by cultured synovial cells in response to interleukin 1 and tumor necrosis factor" <u>Rheumatol. Int.</u> 12:13-16 (1992)			
Examiner		Date Considered 10/11/05		
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>				

FORM PTO-1449 JAN 12 2004 LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P0706P2C2D2C1	Serial No. 10/666,689
			Applicant Lee et al.	
			Filing Date 19 Sep 2003	Group 1646
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)				
1	*41	Holmes et al., "Structure and Functional Expression of a Human Interleukin-8 Receptor" <u>Science</u> 253(5025):1278-1280 (1991)		
2	42	Horuk et al., "Purification, Receptor Binding Analysis, and Biological Characterization of Human Melanoma Growth Stimulating Activity (MGSA)" <u>Journal of Biological Chemistry</u> 268(1):541-546 (1993)		
2	*43	Jazin et al., "A proposed bovine neuropeptide Y (NPY) receptor cDNA clone, or its human homologue, confers neither NPY binding sites nor NPY responsiveness on transfected cells" <u>Regulatory Peptides</u> 47:247-258 (1993)		
2	*44	Kahan, "Immunosuppressive therapy" <u>Current Opinion in Immunology</u> 4(5):553-560 (Oct 1992)		
2	45	Keller, G. H. et al., "Molecular Hybridization Technology" <u>DNA Probes</u> , New York, NY:Stockton Press pps. xv-xvi; 2-27 (1989)		
2	*46	Koch et al., "Interleukin-8 as a Macrophage-Derived Mediator of Angiogenesis" <u>Science</u> 258:1798-1801 (1992)		
2	47	Koch et al., "Interleukin-8 is a potent human macrophage-derived mediator of angiogenesis that is blocked by interleukin-8 antibody and antisense oligonucleotide" <u>Arthritis and Rheumatism</u> (abstract #86) 35(9 Supp.):S49 (1992)		
2	*48	Koch et al., "Synovial tissue macrophage as a source of the chemotactic cytokine IL-8" <u>J. Immunol.</u> 147(7):2187-2195 (1991)		
2	*49	Kubo et al., "Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor" <u>Nature</u> 323:411-416 (1986)		
2	*50	LaRosa et al., "Amino terminus of the interleukin-8 receptor is a major determinant of receptor subtype specificity" <u>Journal of Biological Chemistry</u> 267(35):25402-25406 (1992)		
2	*51	Lee et al., "Characterization of Complementary DNA Clones Encoding the Rabbit IL-8 Receptor" <u>Journal of Immunology</u> 148(4):1261-1264 (Feb 15, 1992)		
2	*52	Lee et al., "Characterization of Two High Affinity Human Interleukin-8 Receptors" <u>Journal of Biological Chemistry</u> 267(23):16283-16287 (1992)		
2	*53	Lerner, R.A., "Tapping the Immunological Repertoire to Produce Antibodies of Predetermined Specificity" <u>Nature</u> 299:592-596 (Oct 1982)		
2	*54	Lindley et al., "NAP-1/IL-8 in Rheumatoid Arthritis" <u>Advances in Experimental Medicine and Biology</u> (Chemotactic Cytokines: Biology of the Inflammatory Peptide Supergene Family), Westwick, J. et al. (eds) Vol. 305:147-156 (1991)		
2	*55	Loetscher et al., "Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes" <u>Journal of Biological Chemistry</u> 269(1):232-237 (1994)		
2	*56	Mahida et al., "Enhanced synthesis of neutrophil-activating peptide-I/interleukin-8 in active ulcerative colitis" <u>Clinical Science</u> 82:273-275 (1992)		
2	*57	Mattoli et al., "Expression of the Potent Inflammatory Cytokines, GM-CSF, IL6, and IL8, in Bronchial Epithelial Cells of Asthmatic Patients" 101(3):27S-29S (1992)		
2	*58	Moser et al., "Interleukin-8 Antagonists Generated by N-terminal Modification" <u>Journal of Biological Chemistry</u> 268(10):7125-7128 (1993)		
2	*59	Murphy and Tiffany, "Cloning of complementary DNA encoding a functional human interleukin-8 receptor" <u>Science</u> 253(5025):1280-1283 (Sep 13, 1991)		
2	*60	Nomura, H. et al., "Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte chemotactic peptide receptors" <u>International Immunology</u> 5(10):1239-1249 (1993)		
Examiner			Date Considered 10/11/09	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449 JAN 12 2004 LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P0706P2C2D2C1	Serial No. 10/666,689
		Applicant Lee et al.		
		Filing Date 19 Sep 2003	Group 1646	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)				
1	*61	Oppenheim et al., "Properties of the novel proinflammatory supergene intercine" cytokine family" <u>Ann. Rev. Immunol.</u> 9:617-648 (1991)		
2	62	Peichl et al., "Human neutrophil activating peptide/interleukin 8 acts as an autoantigen in rheumatoid arthritis" <u>Annals Rheum. Dis.</u> 51:19-22 (1992)		
2	*63	Peralta et al., "Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors" <u>EMBO Journal</u> 6:3923-3929 (1987)		
2	64	Porat et al., "Interleukin-1 (IL-1) receptor blockade reduces endotoxin and Borrelia burgdorferi-stimulated IL-8 synthesis in human mononuclear cells" <u>FASEB J.</u> 6(7):2482-2486 (1992)		
2	*65	Prado et al. <u>Journal of Biological Chemistry</u> 269(17):12391-12394 (April 29, 1994)		
2	*66	Quan, J.M. et al., "Antibodies against the N-terminus of IL-8 receptor A inhibit neutrophil chemotaxis" <u>Biochem. & Biophys. Res. Comm.</u> 219:405-411 (1996)		
2	*67	Ramachandran et al., "The Structural and Functional Interrelationships of Muscarinic Acetylcholine Receptor Subtypes" <u>Bioessays</u> 10:54-57 (1989)		
2	68	Rampart et al., "Development and Application of a Radioimmunoassay for Interleukin-8: Detection of Interleukin-8 Synovial Fluids from Patients with Inflammatory Joint Disease" <u>Laboratory Investigations</u> 66(4):512-518 (1992)		
2	*69	Samanta et al., "Identification and characterization of specific receptors for monocyte-derived neutrophil chemotactic factor (MDNCF) on human neutrophils" <u>Journal of Experimental Medicine</u> 169:1185-1189 (1989)		
2	*70	Saragovi et al., "The Murine Interleukin 2 Receptor: Irreversible Cross-Linking of Radiolabeled Interleukin 2 to High Affinity Interleukin 2 Receptors Reveals a Noncovalently Associated Subunit" <u>J. Immunol.</u> 139(6):1918-1926 (Sep. 15, 1987)		
2	71	Seitz et al., "Enhanced Production of Neutrophil-activating Peptide-1/Interleukin-8 in Rheumatoid Arthritis" <u>J. Clin. Invest.</u> 87(2):463-469 (1991)		
2	72	Seitz et al., "Interleukin-8 in inflammatory rheumatic diseases: synovial fluid levels, relation to rheumatoid factors, production by mononuclear cells, and effects of gold sodium thiomalate and methotrexate" <u>Rheumatology</u> 12:159-164 (1992)		
2	*73	Sevier et al., "Monoclonal Antibodies in Clinical Immunology" <u>Clinical Chemistry</u> 27(11):1797-1806 (1981)		
2	*74	Sims et al., "cDNA Expression Cloning of the IL-1 Receptor, a Member of the Immunoglobulin Superfamily" <u>Science</u> 241:585-589 (1988)		
2	75	Smyth et al., "IL-8 Gene Expression and Production in Human Peripheral Blood Lymphocyte Subsets" <u>J. Immunol.</u> 146(11):3815-3823		
2	76	Soh et al., "Identification and Sequence of an Accessory Factor Required for Activation of the Human Interferon γ Receptor" <u>Cell</u> 76:793-802 (1994)		
2	*77	Sticherling et al., "Production and Characterization of Monoclonal Antibodies Against the Novel Neutrophil Activating Peptide NAP/IL-8" <u>J. Immunol.</u> 143(5):1628-1634 (September 1, 1989)		
2	*78	Strader et al., "Structural basis of α -adrenergic receptor function" <u>FASEB</u> 3:1825-1832 (1989)		
2	*79	Taylor, C. W., "The role of G proteins in transmembrane signalling" <u>Biochemical Journal</u> 272(1):1-13 (1990)		
2	*80	Terkeltaub et al., "Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystal-induced inflammation" <u>Arthr. and Rheum.</u> 34:894-903 (1991)		
Examiner			Date Considered 10/18/05	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				



***Examine**

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.